You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Prospects diverge for 2 experimental drugs

Prospects for two experimental drugs important to Massachusetts biotechnology companies diverged Monday, with one moving forward and the other facing a delay.

ImmunoGen Inc. of Waltham said its partner, the Genentech division of Swiss drug maker Roche AG, has applied to the Food and Drug Administration for approval of a promising breast cancer drug using ImmunoGen’s technology. If the agency grants accelerated approval for the drug, it could be on the market by early next year.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week